Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer

Published:2019-04-09 Issue:9 Volume:62 Page:4716-4730
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Zhang Yan¹²³,Wu Xishan¹²³,Xue Xiaoqian¹⁴,Li Chenchang¹,Wang Junjian⁵,Wang Rui¹,Zhang Cheng¹⁶,Wang Chao¹²³,Shi Yudan¹²³,Zou Lingjiao¹²³,Li Qiu¹²³,Huang Zenghong,Hao Xiaojuan⁷^ORCID,Loomes Kerry⁸,Wu Donghai⁹,Chen Hong-Wu,Xu Jinxin⁹,Xu Yong¹³^ORCID

Affiliation:

1. Guangdong Provincial Key Laboratory of Biocomputing, Joint School of Life Sciences, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou Medical University, Guangzhou 510530, China

2. University of Chinese Academy of Sciences, No. 19 Yuquan Road, Beijing 100049, China

3. Guangzhou Regenerative Medicine and Health Guangdong Laboratory (GRMH-GDL), Guangzhou 510530, China

4. School of Life Science, Huizhou University, Huizhou 516007, China

5. School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China

6. School of Pharmaceutical Sciences, Jilin University, No.1266 Fujin Road, Chaoyang District, Changchun, Jilin 130021, China

7. Manufacturing, Commonwealth Scientific and Industrial Research Organization (CSIRO), Clayton, Vic 3168, Australia

8. School of Biological Sciences & Maurice Wilkins Centre, University of Auckland, Auckland 1010, New Zealand

9. Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China

Funder

National Natural Science Foundation of China

Chinese Academy of Sciences

U.S. Department of Defense

Ministry of Science and Technology of the People's Republic of China

Prostate Cancer Foundation

National Cancer Institute

Guangdong Provincial Key Laboratory of Biocomputing

Guangzhou Regenerative Medicine and Health Guangdong Laboratory

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b00327

Reference54 articles.

1. Cancer statistics, 2014

2. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012

3. AACR Cancer Progress Report 2015

4. STUDIES ON PROSTATIC CANCER

5. Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and pharmacological characterization of 1,2,3,4-tetrahydroquinoline derivatives as RORγ inverse agonists against prostate cancer;Acta Pharmacologica Sinica;2024-05-02

2. Discovery of the First-in-Class RORγ Covalent Inhibitors for Treatment of Castration-Resistant Prostate Cancer;Journal of Medicinal Chemistry;2024-01-16

3. Discovery and SAR of JTE-151: A Novel RORγ Inhibitor for Clinical Development;Journal of Medicinal Chemistry;2024-01-03

4. Identification of dietary compounds that interact with the circadian clock machinery: Molecular docking and structural similarity analysis;Journal of Molecular Graphics and Modelling;2023-09

5. Design and synthesis of 4-acetoxypentanamide derivatives of spliceostatin A and their biological evaluation towards prostate cancer treatment;Bioorganic & Medicinal Chemistry Letters;2023-07